Novel Therapeutics in Glaucoma Management

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2017 Sep 20

PMID 28925883

Citations 20

Authors

Claudio Bucolo

Chiara Bianca Maria Platania

Filippo Drago

Vincenza Bonfiglio

Michele Reibaldi

Teresio Avitabile

Maurizio Uva

Affiliations

Soon will be listed here.

Abstract

Background: Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms.

Objective: An overview of the ultimate promising experimental drugs to manage glaucoma has been provided.

Results: In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors.

Conclusions: The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.

Citing Articles

Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists.

Sharif N, Millar J, Zode G, Ota T Int J Mol Sci. 2024; 25(6).

PMID: 38542305 PMC: 10970031. DOI: 10.3390/ijms25063328.

The landscape of nanoparticle-based siRNA delivery and therapeutic development.

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y Mol Ther. 2024; 32(2):284-312.

PMID: 38204162 PMC: 10861989. DOI: 10.1016/j.ymthe.2024.01.005.

Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients.

Sharif N Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375739 PMC: 10304251. DOI: 10.3390/ph16060791.

Rho Kinase Inhibitors as a Neuroprotective Pharmacological Intervention for the Treatment of Glaucoma.

Thomas N, Nagrale P Cureus. 2022; 14(8):e28445.

PMID: 36176819 PMC: 9512308. DOI: 10.7759/cureus.28445.

Comprehensive Evidence of Carrier-Mediated Distribution of Amantadine to the Retina across the Blood-Retinal Barrier in Rats.

Shinozaki Y, Akanuma S, Mori Y, Kubo Y, Hosoya K Pharmaceutics. 2021; 13(9).

PMID: 34575415 PMC: 8469395. DOI: 10.3390/pharmaceutics13091339.

References

Jacobson K, Civan M . Ocular Purine Receptors as Drug Targets in the Eye. J Ocul Pharmacol Ther. 2016; 32(8):534-547. PMC: 5069731. DOI: 10.1089/jop.2016.0090. View

Knipstein J, Gore L . Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs. 2011; 20(10):1455-67. DOI: 10.1517/13543784.2011.613822. View

Matsumura R, Inoue T, Matsumura A, Tanihara H . Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study. Clin Drug Investig. 2017; 37(6):535-539. DOI: 10.1007/s40261-017-0509-0. View

Akhter N, Nix M, Abdul Y, Singh S, Husain S . Delta-opioid receptors attenuate TNF-α-induced MMP-2 secretion from human ONH astrocytes. Invest Ophthalmol Vis Sci. 2013; 54(10):6605-11. PMC: 3803137. DOI: 10.1167/iovs.13-12196. View

Lambert W, Carlson B, Formichella C, Sappington R, Ahlem C, Calkins D . Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma. Front Neurosci. 2017; 11:45. PMC: 5293777. DOI: 10.3389/fnins.2017.00045. View

Pfeiffer N, Lamparter J, Gericke A, Grus F, Hoffmann E, Wahl J . Neuroprotection of medical IOP-lowering therapy. Cell Tissue Res. 2013; 353(2):245-51. DOI: 10.1007/s00441-013-1671-1. View

Perez de Lara M, Guzman-Aranguez A, de la Villa P, Diaz-Hernandez J, Miras-Portugal M, Pintor J . Increased levels of extracellular ATP in glaucomatous retinas: Possible role of the vesicular nucleotide transporter during the development of the pathology. Mol Vis. 2015; 21:1060-70. PMC: 4558477. View

Charalampopoulos I, Alexaki V, Lazaridis I, Dermitzaki E, Avlonitis N, Tsatsanis C . G protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone. FASEB J. 2006; 20(3):577-9. DOI: 10.1096/fj.05-5078fje. View

Zaidel-Bar R, Zhenhuan G, Luxenburg C . The contractome--a systems view of actomyosin contractility in non-muscle cells. J Cell Sci. 2015; 128(12):2209-17. DOI: 10.1242/jcs.170068. View

10.

Vidal L, Diaz F, Villena A, Moreno M, Campos J, Perez de Vargas I . Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res Bull. 2010; 82(1-2):18-24. DOI: 10.1016/j.brainresbull.2010.02.011. View

11.

Hu H, Lu W, Zhang M, Zhang X, Argall A, Patel S . Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res. 2010; 91(3):425-32. PMC: 2941978. DOI: 10.1016/j.exer.2010.06.017. View

12.

Wang W, Townes-Anderson E . LIM Kinase, a Newly Identified Regulator of Presynaptic Remodeling by Rod Photoreceptors After Injury. Invest Ophthalmol Vis Sci. 2015; 56(13):7847-58. PMC: 4682489. DOI: 10.1167/iovs.15-17278. View

13.

Matteucci A, Varano M, Gaddini L, Mallozzi C, Villa M, Pricci F . Neuroprotective effects of citicoline in in vitro models of retinal neurodegeneration. Int J Mol Sci. 2014; 15(4):6286-97. PMC: 4013628. DOI: 10.3390/ijms15046286. View

14.

Juhl C, Els-Heindl S, Schonauer R, Redlich G, Haaf E, Wunder F . Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential. ChemMedChem. 2016; 11(21):2378-2384. DOI: 10.1002/cmdc.201600307. View

15.

Juttler E, Potrovita I, Tarabin V, Prinz S, Dong-Si T, Fink G . The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology. 2004; 47(4):580-92. DOI: 10.1016/j.neuropharm.2004.05.009. View

16.

Van de Velde S, De Groef L, Stalmans I, Moons L, Van Hove I . Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. Prog Neurobiol. 2015; 131:105-19. DOI: 10.1016/j.pneurobio.2015.06.002. View

17.

Banitt M, Ventura L, Feuer W, Savatovsky E, Luna G, Shif O . Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol Vis Sci. 2013; 54(3):2346-52. PMC: 3626526. DOI: 10.1167/iovs.12-11026. View

18.

Cellini M, Versura P, Trere D, Campos E . Effects of endothelin-1 on human trabecular meshwork cell contraction. an in vitro cell culture model. Ophthalmic Res. 2005; 37(1):43-9. DOI: 10.1159/000083021. View

19.

Chowdhury U, Holman B, Fautsch M . ATP-sensitive potassium (K(ATP)) channel openers diazoxide and nicorandil lower intraocular pressure in vivo. Invest Ophthalmol Vis Sci. 2013; 54(7):4892-9. PMC: 3720149. DOI: 10.1167/iovs.13-11872. View

20.

Thomas T, Shih T . Stimulation of central A1 adenosine receptors suppresses seizure and neuropathology in a soman nerve agent seizure rat model. Toxicol Mech Methods. 2014; 24(6):385-95. DOI: 10.3109/15376516.2014.920450. View